MedTrace Logo

Efficacy of Metformin as add-on Therapy in Non-Diabetic Heart Failure Patients

NCT05177588 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 70

Last updated 2023-07-19

No results posted yet for this study

Summary

There is an increasing interest in the use of metformin in CV diseases and there is an increasing interest in studying its potential new roles in heart failure patients. There were some concerns related to the safety of metformin in such diabetic patients due to the risk of lactic acidosis. However, recent studies showed that metformin was safe or even beneficial in HF patients. We hypothesized that metformin might improve morbidity, mortality, cardiac function, and HR-QoL in non-diabetic patients with HFrEF.

Conditions

Interventions

DRUG

Metformin Hydrochloride

Metformin 2000 mg/day

Sponsors & Collaborators

  • Cairo University

    lead OTHER

Principal Investigators

  • Ahmed M Kamel, MSc. · Faculty of Pharmacy, Cairo University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
79 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-07-21
Primary Completion
2023-03-30
Completion
2023-04-30

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05177588 on ClinicalTrials.gov